New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meetin false

ביוליין אר אקס בע"מ	2 380
BIOLINE RX LTD
Corporation no: 513398750	8688

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	30/05/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-039497	Time of broadcast: 15:15 15:15

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

6-K_30-May-25_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2024
Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: info@BioLineRx.com   Company site: www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: phils@biolinerx.com 1
Israel